{"id":"https://openalex.org/W7161978249","doi":"https://doi.org/10.1016/j.esmoop.2026.107471","title":"448P Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in the first line (1L) setting among patients with metastatic triple-negative breast cancer (mTNBC)","display_name":"448P Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in the first line (1L) setting among patients with metastatic triple-negative breast cancer (mTNBC)","publication_year":2026,"publication_date":"2026-05-01","ids":{"openalex":"https://openalex.org/W7161978249","doi":"https://doi.org/10.1016/j.esmoop.2026.107471"},"language":"en","primary_location":{"id":"doi:10.1016/j.esmoop.2026.107471","doi":"https://doi.org/10.1016/j.esmoop.2026.107471","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.esmoop.2026.107471","pdf_url":null,"source":{"id":"https://openalex.org/S4210217024","display_name":"ESMO Open","issn_l":"2059-7029","issn":["2059-7029"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO Open","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1016/j.esmoop.2026.107471","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5073093064","display_name":"K. Punie","orcid":"https://orcid.org/0000-0002-1162-7963","observed_orcids":["https://orcid.org/0000-0002-1162-7963"]},"institutions":[{"id":"https://openalex.org/I4405261247","display_name":"Ziekenhuis aan de Stroom","ror":"https://ror.org/050d0xx93","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I4405261247"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"K. Punie","raw_affiliation_strings":["Department of Medical Oncology, Ziekenhuis Aan de Stroom, Antwerp, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Ziekenhuis Aan de Stroom, Antwerp, Belgium","institution_ids":["https://openalex.org/I4405261247"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5136471560","display_name":"Sara A. Hurvitz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S.A. Hurvitz","raw_affiliation_strings":["Department of Medicine, UW Medicine, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, UW Medicine, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, United States of America","institution_ids":["https://openalex.org/I201448701","https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066183684","display_name":"A. Dasgupta","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Dasgupta","raw_affiliation_strings":["Health Economics Outcomes Research, Gilead Sciences, Inc, Foster City, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Health Economics Outcomes Research, Gilead Sciences, Inc, Foster City, United States of America","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5136621260","display_name":"A. Kaushik","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Kaushik","raw_affiliation_strings":["Health Economics Outcomes Research, Gilead Sciences, Inc., Foster City, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Health Economics Outcomes Research, Gilead Sciences, Inc., Foster City, United States of America","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079186209","display_name":"Catherine Lai","orcid":"https://orcid.org/0009-0002-6364-5431","observed_orcids":["https://orcid.org/0009-0002-6364-5431"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Lai","raw_affiliation_strings":["Executive Director and Global Development - Clinical Development, Gilead Sciences, Inc., Foster City, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Executive Director and Global Development - Clinical Development, Gilead Sciences, Inc., Foster City, United States of America","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5126245531","display_name":"S. Padman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Padman","raw_affiliation_strings":["Director Clinical Development - Oncology, Gilead Sciences, Inc., Miami, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Director Clinical Development - Oncology, Gilead Sciences, Inc., Miami, United States of America","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076675411","display_name":"N. Sjekloca","orcid":"https://orcid.org/0009-0009-9509-0857","observed_orcids":["https://orcid.org/0009-0009-9509-0857"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"N. Sjekloca","raw_affiliation_strings":["Global Medical Affairs, Gilead Sciences, Inc, Foster City, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Medical Affairs, Gilead Sciences, Inc, Foster City, United States of America","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026681845","display_name":"Billy Amzal","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. Amzal","raw_affiliation_strings":["Head of Strategic Consulting, Phastar, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Head of Strategic Consulting, Phastar, Paris, France","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5136623403","display_name":"P. Serafini","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P. Serafini","raw_affiliation_strings":["Data Scientist, Evidinno Outcomes Research Inc., Vancouver, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Data Scientist, Evidinno Outcomes Research Inc., Vancouver, Canada","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5136626560","display_name":"G. Nazar","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. Nazar","raw_affiliation_strings":["Senior Associate Research Scientist, Evidinno Outcomes Research Inc., Vancouver, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Senior Associate Research Scientist, Evidinno Outcomes Research Inc., Vancouver, Canada","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3910,"currency":"USD","value_usd":3910},"apc_paid":{"value":3910,"currency":"USD","value_usd":3910},"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"11","issue":null,"first_page":"107471","last_page":"107471"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.9247999787330627,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.9247999787330627,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.0608999989926815,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.0019000000320374966,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9100000262260437},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8050000071525574},{"id":"https://openalex.org/keywords/surrogate-endpoints","display_name":"surrogate endpoints","score":0.9409999847412109},{"id":"https://openalex.org/keywords/metastatic-triple-negative-breast-cancer","display_name":"metastatic triple-negative breast cancer","score":0.9869999885559082},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.8320000171661377},{"id":"https://openalex.org/keywords/treatment-crossover","display_name":"treatment crossover","score":0.8939999938011169},{"id":"https://openalex.org/keywords/pd-l1-status","display_name":"PD-L1 status","score":0.8349999785423279},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.7289999723434448}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8090999722480774},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.7882999777793884},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.6990000009536743},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6590999960899353},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6474999785423279},{"id":"https://openalex.org/C2993493390","wikidata":"https://www.wikidata.org/wiki/Q5453208","display_name":"First line","level":2,"score":0.46650001406669617},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.3887999951839447},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.37720000743865967},{"id":"https://openalex.org/C2987804222","wikidata":"https://www.wikidata.org/wiki/Q5376582","display_name":"End point","level":2,"score":0.37279999256134033},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.36809998750686646},{"id":"https://openalex.org/C141341695","wikidata":"https://www.wikidata.org/wiki/Q2368661","display_name":"Surrogate endpoint","level":2,"score":0.3529999852180481},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.31220000982284546},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.2939000129699707},{"id":"https://openalex.org/C2780558122","wikidata":"https://www.wikidata.org/wiki/Q7310803","display_name":"Relative survival","level":4,"score":0.2874000072479248},{"id":"https://openalex.org/C2776283816","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Survival rate","level":2,"score":0.27810001373291016},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.2694000005722046},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.259799987077713},{"id":"https://openalex.org/C2993277928","wikidata":"https://www.wikidata.org/wiki/Q7248370","display_name":"Prognostic model","level":3,"score":0.25600001215934753},{"id":"https://openalex.org/C28719098","wikidata":"https://www.wikidata.org/wiki/Q44946","display_name":"Point (geometry)","level":2,"score":0.2502000033855438}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.esmoop.2026.107471","doi":"https://doi.org/10.1016/j.esmoop.2026.107471","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.esmoop.2026.107471","pdf_url":null,"source":{"id":"https://openalex.org/S4210217024","display_name":"ESMO Open","issn_l":"2059-7029","issn":["2059-7029"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO Open","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.esmoop.2026.107471","doi":"https://doi.org/10.1016/j.esmoop.2026.107471","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.esmoop.2026.107471","pdf_url":null,"source":{"id":"https://openalex.org/S4210217024","display_name":"ESMO Open","issn_l":"2059-7029","issn":["2059-7029"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO Open","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7162561282","https://openalex.org/W3014332654","https://openalex.org/W4379285574","https://openalex.org/W2057735943","https://openalex.org/W2404165994","https://openalex.org/W2999546558","https://openalex.org/W2006669086","https://openalex.org/W2943916503","https://openalex.org/W2331485444","https://openalex.org/W2166396356"],"abstract_inverted_index":{"OS":[0,29,32,56],"is":[1,44],"often":[2],"considered":[3],"the":[4],"gold":[5],"standard":[6,23],"in":[7,57],"oncology":[8],"trials":[9],"for":[10,55],"evaluating":[11],"treatment":[12,15,59],"efficacy.":[13],"However,":[14],"crossovers":[16,41],"(as":[17],"part":[18],"of":[19,24,45,60],"study":[20],"design":[21],"or":[22],"care":[25],"[SOC])":[26],"can":[27,51],"confound":[28],"interpretation.":[30],"Predicting":[31],"from":[33],"a":[34,53],"surrogate":[35,54],"end":[36],"point":[37],"not":[38],"affected":[39],"by":[40,64],"(eg,":[42],"PFS)":[43],"interest.":[46],"We":[47],"evaluated":[48],"if":[49],"PFS":[50],"be":[52],"1L":[58],"mTNBC":[61],"(overall":[62],"and":[63],"programmed":[65],"death":[66],"ligand":[67],"1":[68],"[PD-L1]":[69],"status).":[70]},"counts_by_year":[],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2026-05-22T00:00:00"}